EnteroMedics Performance
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and EnteroMedics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days EnteroMedics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, EnteroMedics is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Fifty Two Week Low | 1.96 | |
| Fifty Two Week High | 2.09 |
EnteroMedics |
EnteroMedics Relative Risk vs. Return Landscape
If you would invest (100.00) in EnteroMedics on January 24, 2024 and sell it today you would earn a total of 100.00 from holding EnteroMedics or generate -100.0% return on investment over 90 days. EnteroMedics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than EnteroMedics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
EnteroMedics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for EnteroMedics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as EnteroMedics, and traders can use it to determine the average amount a EnteroMedics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ETRM |
Based on monthly moving average EnteroMedics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of EnteroMedics by adding EnteroMedics to a well-diversified portfolio.
EnteroMedics Fundamentals Growth
EnteroMedics Stock prices reflect investors' perceptions of the future prospects and financial health of EnteroMedics, and EnteroMedics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on EnteroMedics Stock performance.
| Return On Equity | -146.32 | |||
| Return On Asset | -48.42 | |||
| Current Valuation | 5.39 M | |||
| Shares Outstanding | 14.57 M | |||
| Price To Earning | (0.32) X | |||
| Price To Book | 0.45 X | |||
| Price To Sales | 52.22 X | |||
| Revenue | 571.76 K | |||
| EBITDA | (22.15 M) | |||
| Cash And Equivalents | 11.2 M | |||
| Cash Per Share | 1.35 X | |||
| Debt To Equity | 4.91 % | |||
| Book Value Per Share | 4.58 X | |||
| Cash Flow From Operations | (18.25 M) | |||
| Earnings Per Share | (6.50) X | |||
| Total Asset | 11.59 M | |||
| Retained Earnings | (277.58 M) | |||
| Current Asset | 10.5 M | |||
| Current Liabilities | 4.49 M | |||
Things to note about EnteroMedics performance evaluation
Checking the ongoing alerts about EnteroMedics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for EnteroMedics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| EnteroMedics is not yet fully synchronised with the market data | |
| EnteroMedics has some characteristics of a very speculative penny stock | |
| EnteroMedics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 571.76 K. Net Loss for the year was (25.16 M) with profit before overhead, payroll, taxes, and interest of 355.18 K. | |
| EnteroMedics currently holds about 11.2 M in cash with (18.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.35. |
- Analyzing EnteroMedics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether EnteroMedics' stock is overvalued or undervalued compared to its peers.
- Examining EnteroMedics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating EnteroMedics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of EnteroMedics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of EnteroMedics' stock. These opinions can provide insight into EnteroMedics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in EnteroMedics Stock
If you are still planning to invest in EnteroMedics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EnteroMedics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |